Current Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 54)
Current Health logo

Current Health

ChallengerHealthcare

Remote Patient Monitoring & Hospital-at-Home Platform

Current Health is a remote patient monitoring platform re-acquired by co-founder Christopher McGhee from Best Buy in mid-2025 after Best Buy paid $400M for it in 2021;

AI VisibilityBeta
Overall Score
C54
Category Rank
#210 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
59
Perplexity
50
Gemini
56

About

Current Health is a remote patient monitoring (RPM) and hospital-at-home technology company originally founded in Edinburgh, Scotland, and later headquartered in the United States. The platform integrates wearable vital sign monitors, connected medical devices, telehealth, and patient engagement tools into a unified care delivery system that enables healthcare providers to remotely monitor and manage patients with chronic conditions, acute illness, or post-surgical needs from their own homes. Current Health's platform connects patient-generated health data in real time to clinical care teams through HIPAA-compliant infrastructure, with integrations into major electronic health record (EHR) systems.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

54
Overall Score
93
#210
Category Rank
#1
75
AI Consensus
80
stable
Trend
stable
59
ChatGPT
94
50
Perplexity
89
56
Gemini
94
49
Claude
92
53
Grok
98

Key Details

Category
Remote Patient Monitoring & Hospital-at-Home Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.